SI3033327T1 - (-) - (2R, 3S) -2-AMINO-3-HYDROXY-3-PYRIDIN-4-YL-1-PYROLIDIN-1-ILL- PROPAN- 1-ON (L) - (+) TARTRATED SOLE AND METHOD FOR ITS PRODUCTION AND ITS USE - Google Patents
(-) - (2R, 3S) -2-AMINO-3-HYDROXY-3-PYRIDIN-4-YL-1-PYROLIDIN-1-ILL- PROPAN- 1-ON (L) - (+) TARTRATED SOLE AND METHOD FOR ITS PRODUCTION AND ITS USE Download PDFInfo
- Publication number
- SI3033327T1 SI3033327T1 SI201430670T SI201430670T SI3033327T1 SI 3033327 T1 SI3033327 T1 SI 3033327T1 SI 201430670 T SI201430670 T SI 201430670T SI 201430670 T SI201430670 T SI 201430670T SI 3033327 T1 SI3033327 T1 SI 3033327T1
- Authority
- SI
- Slovenia
- Prior art keywords
- salt
- pyridin
- hydroxy
- amino
- pyrrolidin
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract 11
- GRZMKKUGHIECFK-MNOVXSKESA-N (2r,3s)-2-amino-3-hydroxy-3-pyridin-4-yl-1-pyrrolidin-1-ylpropan-1-one Chemical compound C1([C@H](O)[C@@H](N)C(=O)N2CCCC2)=CC=NC=C1 GRZMKKUGHIECFK-MNOVXSKESA-N 0.000 title claims abstract 4
- 238000004519 manufacturing process Methods 0.000 title claims 2
- 150000003839 salts Chemical class 0.000 claims abstract 15
- 208000002193 Pain Diseases 0.000 claims abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 2
- 208000010877 cognitive disease Diseases 0.000 claims 5
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 208000024827 Alzheimer disease Diseases 0.000 claims 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 3
- 201000004810 Vascular dementia Diseases 0.000 claims 3
- 201000007201 aphasia Diseases 0.000 claims 3
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 208000000094 Chronic Pain Diseases 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 2
- 206010039966 Senile dementia Diseases 0.000 claims 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 2
- 208000029028 brain injury Diseases 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 238000000634 powder X-ray diffraction Methods 0.000 claims 2
- 230000000750 progressive effect Effects 0.000 claims 2
- 208000020016 psychiatric disease Diseases 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 238000001228 spectrum Methods 0.000 claims 2
- 150000003892 tartrate salts Chemical class 0.000 claims 2
- -1 (-) - (2R, 3S) -2-amino-3-hydroxy-3-pyridin-4-yl-1-pyrrolidin-1-yl-propan- - (+) tartrate salts Chemical class 0.000 claims 1
- IMZCCWFKFDCYIV-NEPJUHHUSA-N (1S,2R)-2-amino-1-pyridin-4-yl-3-pyrrolidin-1-ylpropan-1-ol Chemical compound N[C@H](CN1CCCC1)[C@@H](O)C1=CC=NC=C1 IMZCCWFKFDCYIV-NEPJUHHUSA-N 0.000 claims 1
- GRZMKKUGHIECFK-GHMZBOCLSA-N (2r,3r)-2-amino-3-hydroxy-3-pyridin-4-yl-1-pyrrolidin-1-ylpropan-1-one Chemical compound C1([C@@H](O)[C@@H](N)C(=O)N2CCCC2)=CC=NC=C1 GRZMKKUGHIECFK-GHMZBOCLSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000006888 Agnosia Diseases 0.000 claims 1
- 241001047040 Agnosia Species 0.000 claims 1
- 208000000044 Amnesia Diseases 0.000 claims 1
- 208000031091 Amnestic disease Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010003062 Apraxia Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 208000011990 Corticobasal Degeneration Diseases 0.000 claims 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 1
- 206010012218 Delirium Diseases 0.000 claims 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
- 206010013654 Drug abuse Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000020358 Learning disease Diseases 0.000 claims 1
- 208000009829 Lewy Body Disease Diseases 0.000 claims 1
- 201000002832 Lewy body dementia Diseases 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 206010061285 Mental disorder due to a general medical condition Diseases 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 208000005314 Multi-Infarct Dementia Diseases 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000006289 Rett Syndrome Diseases 0.000 claims 1
- 208000018642 Semantic dementia Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000037132 Subdural Chronic Hematoma Diseases 0.000 claims 1
- 208000002667 Subdural Hematoma Diseases 0.000 claims 1
- 231100000643 Substance intoxication Toxicity 0.000 claims 1
- 206010070863 Toxicity to various agents Diseases 0.000 claims 1
- 206010063661 Vascular encephalopathy Diseases 0.000 claims 1
- 230000006986 amnesia Effects 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000004209 confusion Diseases 0.000 claims 1
- 238000002425 crystallisation Methods 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 206010013395 disorientation Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010014599 encephalitis Diseases 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 208000003906 hydrocephalus Diseases 0.000 claims 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 201000003723 learning disability Diseases 0.000 claims 1
- 208000027061 mild cognitive impairment Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- BGUWFUQJCDRPTL-UHFFFAOYSA-N pyridine-4-carbaldehyde Chemical compound O=CC1=CC=NC=C1 BGUWFUQJCDRPTL-UHFFFAOYSA-N 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000013223 septicemia Diseases 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/255—Tartaric acid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361866155P | 2013-08-15 | 2013-08-15 | |
| EP14755535.3A EP3033327B1 (en) | 2013-08-15 | 2014-08-14 | (-)-(2r,3s)-2-amino-3-hydroxy-3-pyridin-4-yl-1-pyrrolidin-1-yl-propan-1-one (l)-(+) tartrate salt, its method of production and use |
| PCT/US2014/051007 WO2015023816A1 (en) | 2013-08-15 | 2014-08-14 | (-)-(2r,3s)-2-amino-3-hydroxy-3-pyridin-4-yl-1-pyrrolidin-1-yl-propan-1-one (l)-(+) tartrate salt, its method of production and use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI3033327T1 true SI3033327T1 (en) | 2018-05-31 |
Family
ID=51398940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201430670T SI3033327T1 (en) | 2013-08-15 | 2014-08-14 | (-) - (2R, 3S) -2-AMINO-3-HYDROXY-3-PYRIDIN-4-YL-1-PYROLIDIN-1-ILL- PROPAN- 1-ON (L) - (+) TARTRATED SOLE AND METHOD FOR ITS PRODUCTION AND ITS USE |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9242935B2 (https=) |
| EP (2) | EP3033327B1 (https=) |
| JP (1) | JP6486358B2 (https=) |
| CN (2) | CN108794386B (https=) |
| CA (1) | CA2921385C (https=) |
| DK (1) | DK3033327T3 (https=) |
| ES (1) | ES2664749T3 (https=) |
| HU (1) | HUE036381T2 (https=) |
| NO (1) | NO2960430T3 (https=) |
| PL (1) | PL3033327T3 (https=) |
| PT (1) | PT3033327T (https=) |
| SI (1) | SI3033327T1 (https=) |
| WO (1) | WO2015023816A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2921385C (en) | 2013-08-15 | 2021-10-19 | Allergan, Inc. | (-)-(2r,3s)-2-amino-3-hydroxy-3-pyridin-4-yl-1-pyrrolidin-1-yl-propan-1-one (l)-(+) tartrate salt, its method of production and use |
| US9992703B2 (en) * | 2016-04-04 | 2018-06-05 | Cisco Technology, Inc. | Insertion of management packet into a deterministic track |
| US20250161264A1 (en) * | 2022-02-11 | 2025-05-22 | Gilgamesh Pharmaceuticals, Inc. | (ampar-pam)-nmda receptor antagonist combination therapy for treatment of mental conditions and disorders |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5545745A (en) * | 1994-05-23 | 1996-08-13 | Sepracor, Inc. | Enantioselective preparation of optically pure albuterol |
| AU2002348261A1 (en) * | 2001-11-26 | 2003-06-10 | Genzyme Corporation | Diastereoselective synthesis of udp-glucose : n-acylsphingosine glucosyltransferase inhibitors |
| US20090088433A1 (en) * | 2005-01-26 | 2009-04-02 | Bertrand Leblond | Methods of using as analgesics 1-benzyl-1-hydroxy-2,3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds |
| WO2008011483A2 (en) * | 2006-07-19 | 2008-01-24 | Allergan, Inc. | Methods for treating chronic pain using 1- (hetero) aryl-1-hydroxy 2,3-diamino-propyl amines and related compounds |
| WO2008011478A2 (en) * | 2006-07-19 | 2008-01-24 | Allergan, Inc. | Methods for treating chronic pain using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds |
| JP2010520299A (ja) * | 2007-03-06 | 2010-06-10 | アラーガン、インコーポレイテッド | ３−アリール−３−ヒドロキシ−２−アミノ−プロピオン酸アミド、３−ヘテロアリール−３−ヒドロキシ−２−アミノ−プロピオン酸アミドおよび関連化合物を使用する認知障害の処置方法 |
| US8173683B2 (en) * | 2007-03-06 | 2012-05-08 | Allergan, Inc. | Methods for treating cognitive disorders |
| WO2008109286A1 (en) * | 2007-03-06 | 2008-09-12 | Allergan, Inc. | Methods for treating cognitive disorders using 1-aryl-1-hydroxy-2,3-diamino-propyl amines, 1-heteroaryl-1-hydroxy-2,3-diamino-propyl amines and related compounds |
| CA2921385C (en) | 2013-08-15 | 2021-10-19 | Allergan, Inc. | (-)-(2r,3s)-2-amino-3-hydroxy-3-pyridin-4-yl-1-pyrrolidin-1-yl-propan-1-one (l)-(+) tartrate salt, its method of production and use |
-
2014
- 2014-08-14 CA CA2921385A patent/CA2921385C/en active Active
- 2014-08-14 CN CN201810276093.9A patent/CN108794386B/zh active Active
- 2014-08-14 DK DK14755535.3T patent/DK3033327T3/en active
- 2014-08-14 PL PL14755535T patent/PL3033327T3/pl unknown
- 2014-08-14 ES ES14755535.3T patent/ES2664749T3/es active Active
- 2014-08-14 US US14/459,551 patent/US9242935B2/en active Active
- 2014-08-14 PT PT147555353T patent/PT3033327T/pt unknown
- 2014-08-14 EP EP14755535.3A patent/EP3033327B1/en active Active
- 2014-08-14 SI SI201430670T patent/SI3033327T1/en unknown
- 2014-08-14 EP EP18150038.0A patent/EP3336079A1/en not_active Withdrawn
- 2014-08-14 JP JP2016534827A patent/JP6486358B2/ja active Active
- 2014-08-14 CN CN201480050583.7A patent/CN105555765B/zh active Active
- 2014-08-14 WO PCT/US2014/051007 patent/WO2015023816A1/en not_active Ceased
- 2014-08-14 HU HUE14755535A patent/HUE036381T2/hu unknown
-
2015
- 2015-06-26 NO NO15174003A patent/NO2960430T3/no unknown
- 2015-12-21 US US14/976,926 patent/US9540328B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2921385C (en) | 2021-10-19 |
| CN108794386B (zh) | 2021-06-22 |
| EP3033327B1 (en) | 2018-01-03 |
| US20150051253A1 (en) | 2015-02-19 |
| CN105555765A (zh) | 2016-05-04 |
| EP3033327A1 (en) | 2016-06-22 |
| CN108794386A (zh) | 2018-11-13 |
| ES2664749T3 (es) | 2018-04-23 |
| NO2960430T3 (https=) | 2018-01-06 |
| JP6486358B2 (ja) | 2019-03-20 |
| US9540328B2 (en) | 2017-01-10 |
| US9242935B2 (en) | 2016-01-26 |
| JP2016528255A (ja) | 2016-09-15 |
| HK1224292A1 (zh) | 2017-08-18 |
| CN105555765B (zh) | 2018-05-25 |
| CA2921385A1 (en) | 2015-02-19 |
| HUE036381T2 (hu) | 2018-07-30 |
| EP3336079A1 (en) | 2018-06-20 |
| DK3033327T3 (en) | 2018-04-16 |
| PT3033327T (pt) | 2018-04-04 |
| US20160347712A1 (en) | 2016-12-01 |
| WO2015023816A1 (en) | 2015-02-19 |
| PL3033327T3 (pl) | 2018-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019500004A1 (en) | 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases | |
| PH12013501556A1 (en) | IMIDAZO[5,1-f][1,2,4]TRIAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | |
| ME02390B (me) | Inhibitori beta sekretaze | |
| UA113051C2 (xx) | Гетероциклічні похідні та їх застосування у лікуванні неврологічних розладів | |
| WO2012077932A3 (ko) | 신규한 피라졸로 피리딘 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 포함하는 약학적 조성물 | |
| UA114405C2 (uk) | Феніл-3-азабіцикло[3.1.0]гекс-3-илметанони та їх застосування як лікарського засобу | |
| SI2875011T1 (en) | 5-HT3 receptor antagonists | |
| WO2018060732A3 (en) | Compositions and methods for treating seizure disorders | |
| EA201200002A1 (ru) | Производные индоламида и родственные соединения для использования при лечении нейродегенеративных заболеваний | |
| JP2015511958A5 (https=) | ||
| WO2009158467A3 (en) | Di-substituted phenyl compounds as phosphodiesterase 10 inhibitors | |
| BR112017022568A2 (pt) | compostos e seus usos como inibidores de bace1 | |
| SI3033327T1 (en) | (-) - (2R, 3S) -2-AMINO-3-HYDROXY-3-PYRIDIN-4-YL-1-PYROLIDIN-1-ILL- PROPAN- 1-ON (L) - (+) TARTRATED SOLE AND METHOD FOR ITS PRODUCTION AND ITS USE | |
| HK1207860A1 (en) | 2-phenyl-5-heterocyclyl-tetrahydro-2h-pyran-3-amine compounds for use in the treatment of diabetes and its associated disorders | |
| JP5921576B2 (ja) | ピリドン誘導体を含む医薬組成物 | |
| WO2018023072A3 (en) | Compounds and compositions and uses thereof | |
| HRP20151273T1 (hr) | Heterocikliäśki spojevi fenoksilmetila | |
| WO2008002594A3 (en) | Neuronal circuit-dependent neuroprotection by interaction between nicotinic receptors | |
| WO2008151841A3 (en) | Treatment for alzheimer' s disease | |
| WO2015166045A3 (en) | Alkaline phosphatase for use in the treatment of neurodegenerative and neuronal diseases | |
| EA201990450A1 (ru) | Ингибиторы киназы, содержащей домен с двумя лейциновыми "застежками-молниями" (dlk), для лечения заболевания | |
| CL2014000119A1 (es) | Sal de (r)-3-(6-(4-metilfenil)-piridin-3-iloxi)-1-aza-biciclo[2.2.2]octano; composicion farmaceutica; metodo de preparacion; proceso de prodcucion de la sal y sus precursores; y metodo para prevencion, tratamiento y/o retraso de la progresion de una enfermedad o condicion tal como trastornos psiquiatricos o neurodegenerativos. | |
| WO2008136863A3 (en) | Synthesis of compounds useful as modulators of amyloid-beta production | |
| MX346794B (es) | Nuevas sales cristalinas de adicion de acido de derivado triciclico o hidruro del mismo y metodo de produccion de las mismas. | |
| AR079103A1 (es) | Compuesto de sal de mesilato de (s) -2-(4-(3-fluoro-benciloxi)-bencilamino)-propionamida, forma polimorfica (nf6) , composicion farmaceutica, uso del mismo para la preparacion de un medicamento y su procesos de preparacion |